Cargando…

Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation

Gemcitabine is clinically used to treat certain types of cancers, including pancreatic and biliary cancer. We investigated the signal transduction pathways underlying the local antitumor effects of gemcitabine-eluting membranes (GEMs) implanted in pancreatic/biliary tumor-bearing nude mice. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Sung Ill, Fang, Sungsoon, Baek, Yi-Yong, Lee, Don Haeng, Na, Kun, Lee, Su Yeon, Lee, Dong Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084314/ https://www.ncbi.nlm.nih.gov/pubmed/32111094 http://dx.doi.org/10.3390/ijms21051605

Ejemplares similares

Molecular Mechanism of Local Drug Delivery with Paclitaxel-Eluting Membranes in Biliary and Pancreatic Cancer: New Application for an Old Drug
por: Bang, Sookhee, et al.
Publicado: (2015)

Preclinical evaluation of endoscopic placement of a steroid-eluting metal stent in an in vivo porcine benign biliary stricture model
por: Jang, Sung Ill, et al.
Publicado: (2022)

Safety Evaluation of Paclitaxel-Eluting Biliary Metal Stent with Sodium Caprate in Porcine Biliary Tract
por: Jang, Sung Ill, et al.
Publicado: (2019)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities
por: Kim, Young Saing, et al.
Publicado: (2019)

A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
por: Lee, Hee Seung, et al.
Publicado: (2017)

Synergistic induction of early stage of bone formation by combination of recombinant human bone morphogenetic protein-2 and epidermal growth factor
por: Lee, Jae Hyup, et al.
Publicado: (2015)

Epidermal Growth Factor Receptor in Pancreatic Cancer
por: Oliveira-Cunha, Melissa, et al.
Publicado: (2011)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
por: Lee, Da Eun, et al.
Publicado: (2022)

Epidermal growth factor rs4444903 polymorphism and risk of cholangiocarcinoma. A case control study
por: Gawish, Eman Ahmed, et al.
Publicado: (2023)

Topical application of epidermal growth factor accelerates wound healing by myofibroblast proliferation and collagen synthesis in rat
por: Kwon, Young-Bae, et al.
Publicado: (2006)

Epidermal growth factor-like domain multiple 7 (EGFL7): Expression and possible effect on biliary epithelium growth in cholangiocarcinoma
por: Mammola, Caterina L., et al.
Publicado: (2018)

Metastatic cholangiocarcinoma as a cause of appendicitis: a case report and literature review
por: Kang, Sung Il, et al.
Publicado: (2014)

Epidermal growth factor as a reliable marker of necrotizing enterocolitis in preterm neonates
por: Lee, Na Mi
Publicado: (2020)

Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
por: Chen, Chen, et al.
Publicado: (2020)

Targeted Delivery of Epidermal Growth Factor to the Human Placenta to Treat Fetal Growth Restriction
por: Renshall, Lewis J., et al.
Publicado: (2021)

Epidermal Growth Factor Attenuated the Expression of Inflammatory Cytokines in Human Epidermal Keratinocyte Exposed to Propionibacterium acnes
por: Kim, Ji Min, et al.
Publicado: (2018)

Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity
por: Ko, Sung-Jun, et al.
Publicado: (2014)

Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells
por: Bjånes, Tormod, et al.
Publicado: (2020)

Endoscopic Treatment of Pancreatic Calculi
por: Kim, Yong Hoon, et al.
Publicado: (2014)

Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer
por: Phan, Thuy, et al.
Publicado: (2021)

HOTTIP Enhances Gemcitabine and Cisplatin Resistance Through Sponging miR-637 in Cholangiocarcinoma
por: Gao, Kun, et al.
Publicado: (2021)

Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma
por: Park, Eunhyang, et al.
Publicado: (2015)

Efficacy of a Multiplex Paclitaxel Emission Stent Using a Pluronic(®) Mixture Membrane versus a Covered Metal Stent in Malignant Biliary Obstruction: A Prospective Randomized Comparative Study
por: Jang, Sung Ill, et al.
Publicado: (2017)

Effects of microvascular invasion on clinical outcomes after resection with curative intent for cholangiocarcinoma
por: Song, Bo-Hye, et al.
Publicado: (2020)

Neuroendocrine Changes in Cholangiocarcinoma Growth
por: Sato, Keisaku, et al.
Publicado: (2020)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma
por: Suksawat, Manida, et al.
Publicado: (2022)

Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
por: Kim, Aeri, et al.
Publicado: (2017)

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
por: Chung, Shin-Yi, et al.
Publicado: (2021)

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
por: Faller, Bryan A, et al.
Publicado: (2009)

Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth
por: Wisniewski, David J., et al.
Publicado: (2022)

Can Thymidine Phosphorylase Be a Predictive Marker for Gemcitabine and Doxifluridine Combination Chemotherapy in Cholangiocarcinoma?: Case Series
por: Kang, Myoung Hee, et al.
Publicado: (2014)

The use of epidermal growth factor in dermatological practice
por: Shin, Sun Hye, et al.
Publicado: (2022)

YAC tripeptide of epidermal growth factor promotes the proliferation of HaCaT keratinocytes through activation of EGFR
por: Yoo, Yeon Ho, et al.
Publicado: (2014)

ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation
por: Shen, Chia-Hsing, et al.
Publicado: (2021)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages
por: Deshmukh, Sachin Kumar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_as7ps5o2inlrdauvadhgsfc4lj